{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T21:54:07Z","timestamp":1783979647888,"version":"3.55.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002922.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T00:00:00Z","timestamp":1530230400000}}],"reference-count":420,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002922.pub4","type":"journal-article","created":{"date-parts":[[2018,6,29]],"date-time":"2018-06-29T14:22:21Z","timestamp":1530282141000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Immunosuppressive treatment for proliferative lupus nephritis"],"prefix":"10.1002","volume":"2018","author":[{"given":"David J","family":"Tunnicliffe","sequence":"first","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suetonia C","family":"Palmer","sequence":"additional","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorna","family":"Henderson","sequence":"additional","affiliation":[{"name":"NHS Lothian; Renal Department; Royal Infirmary of Edinburgh Edinburgh UK EH16 4SA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Masson","sequence":"additional","affiliation":[{"name":"Royal Free London NHS Foundation Trust; Department of Renal Medicine; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Tong","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Centre for Kidney Research; Westmead Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davinder","family":"Singh-Grewal","sequence":"additional","affiliation":[{"name":"The Sydney Children's Hospitals Network; Department Paediatric Rheumatology; The Children's Hospital at Westmead Cnr Hainsworth and Hawkesbury Roads Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S","family":"Flanc","sequence":"additional","affiliation":[{"name":"Monash Medical Centre; Department of Nephrology; Clayton Rd Clayton VIC Australia 3168"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A","family":"Roberts","sequence":"additional","affiliation":[{"name":"Monash University; Eastern Health Clinical School; Box Hill VIC Australia 3128"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy"},{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"Diaverum Academy; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,29]]},"reference":[{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub4-BIB0001|cit1","first-page":"vi14","article-title":"Comparison between corticosteroid and mycophenolate mofetil and corticosteroid and cyclophosphamide in the treatment of lupus nephritis [abstract no: FO031]","volume":"22","author":"Abedi","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0002|cit2","first-page":"3096","article-title":"Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study.[Erratum appears in Arthritis Rheumatol. 2015 Feb;67(2):487 Note: Aranow, Cynthia [added]]","volume":"66","author":"ACCESS Trial Group","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0003|cit3","first-page":"501A","article-title":"24 hour protein: creatinine ration (24 PCR), not spot PCR (Spot PCR), should be used to monitor the treatment of severe lupus nephritis (LN): the experience of ACCESS [abstract no: FR-PO604]","volume":"27","author":"Shidham","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0004|cit4","first-page":"265A","article-title":"Ability of spot urine protein\/creatinine ratio (spot PCR) to correctly identify the proteinuria endpoints of complete remission (CR), partial remission (PR), and treatment failure (TF) as determined by 24 hour urine PCR (24 PCR): experience of abatacept and cyclophosphamide combination efficacy and safety study (ACCESS) [abstract no: TH-PO764]","volume":"26","author":"Shidham","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0005|cit5","first-page":"S379","article-title":"Treatment of lupus nephritis with abatacept plus low-dose pulse cyclophosphamide followed by azathioprine (the Euro-Lupus regimen): twenty-four week data from a double-blind controlled trial [abstract no: 884]","volume":"66","author":"Wofsy","year":"2013","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis & Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","article-title":"Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials","volume":"65","author":"Wofsy","year":"2013","journal-title":"Arthritis & Rheumatology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0008|cit8","first-page":"S964","article-title":"Abatacept for lupus nephritis: alternative outcome measures support opposing interpretations of data from a multicenter, randomized, double-blind, placebo-controlled phase II\/III study [abstract]","volume":"63","author":"Wofsy","year":"2011","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub4-BIB0010|cit10","first-page":"47A","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide as induction therapy for lupus nephritis: Aspreva Lupus Management Study (ALMS) results [abstract no: SA-FC057]","volume":"18","author":"Appel","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0011|cit11","unstructured":"Clancy RM Ginzler EM Kim M Association of adiponectin and soluble endothelial protein C receptor (sEPCR) with longitudinal assessments in the induction phase of a randomized multicenter trial comparing mycophenolate mofetil and intravenous cyclophosphamide [abstract no: 263] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/acr.20397","article-title":"Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide","volume":"63","author":"Dall'Era","year":"2011","journal-title":"Arthritis Care & Research"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0013|cit13","first-page":"125","article-title":"Aspreva lupus management study (ALMS): maintenance results analysis by racial subgroup [abstract no: OP0168]","volume":"70","author":"Dooley","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"20","key":"10.1002\/14651858.CD002922.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0015|cit15","unstructured":"Ginzler E Contribution of vascular well being to the therapeutic response in the induction phase of a randomized multicenter trial comparing MMF to IVC [abstract no: 2063] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CA) 2008"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0016|cit16","unstructured":"Ginzler EM Appel GB Dooley MA Isenberg D Jayne D Solomons N Mycophenolate mofetil and intravenous cyclophosphamide in the Aspreva Lupus Management Study (ALMS): efficacy by racial group [abstract no: L13] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/art.25052","article-title":"Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial","volume":"62","author":"Ginzler","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0021|cit18","first-page":"23","article-title":"Lessons from the Aspreva Lupus Management Study [abstract no: SP0073]","volume":"68","author":"Isenberg","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0018|cit19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology"},{"issue":"Supp II","key":"10.1002\/14651858.CD002922.pub4-BIB0019|cit20","first-page":"53","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide as induction for lupus nephritis: ALMS results and BILAG responses [abstract no: OP-0018]","volume":"67","author":"Isenberg","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub4-BIB0020|cit21","first-page":"606","article-title":"Mycophenolate mofetil (MMF, Cellcept) for induction and maintenance treatment of lupus nephritis (LN): baseline demographics of patients from the phase III randomized, controlled ASPREVA Lupus Management Study (ALMS) [abstract no: AB0424]","volume":"66","author":"Isenberg","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0022|cit22","first-page":"25A","article-title":"Results of the Aspreva Lupus Management Study (ALMS) maintenance phase [abstract no: TH-FC111]","volume":"21","author":"Jayne","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0023|cit23","unstructured":"Nadig RS Efficacy, toxicity and tolerability of mycophenolate mofetil in patients with lupus nephritis, based on dose\/weight ratio [abstract no: 431] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0024|cit24","first-page":"S365","article-title":"Response to MMF therapy for lupus nephritis is independent of genetic variation of inosine monophosphate dehydrogenase [abstract no: 837]","volume":"64","author":"Schwartz","year":"2012","journal-title":"Arthritis & Rheumatology"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0025|cit25","first-page":"S365","article-title":"Response to MMF therapy for lupus nephritis is independent of genetic variation of inosine monophosphate dehydrogenase [abstract no: 837]","volume":"64","author":"Schwartz","year":"2012","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0026|cit26","unstructured":"Silva-Fernandez L Nadig RS von Gizycki H Ginzler EM Efficacy, toxicity and tolerability of mycophenolate mofetil in patients with lupus nephritis, based on dose\/weight ratio [abstract no: 431] ACR\/ARHP Annual Scientific Meeting; 2007 Nov 6-11; Boston (MA) 2007"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0961203307084712","article-title":"Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)","volume":"16","author":"Sinclair","year":"2007","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0028|cit28","first-page":"528A","article-title":"Protocol for the Aspreva Lupus Management Study (ALMS) [abstract no: F-PO882]","volume":"16","author":"Sinclair","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Stone DH Dall'Era M Levesque V Cisternas MG Wofsy D Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil (MMF) or pulse cyclophosphamide (IV) [abstract no: 2073] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009","DOI":"10.1002\/acr.20397"},{"issue":"13","key":"10.1002\/14651858.CD002922.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1177\/0961203312458466","article-title":"Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial","volume":"21","author":"Sundel","year":"2012","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0031|cit31","unstructured":"Sundel RP Lisk L Mycophenolate mofetil compared with intravenous cyclophosphamide as induction treatment for pediatric lupus nephritis: a randomized trial [abstract no: 1274] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco, CL 2008"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1053\/j.ajkd.2012.11.042","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study","volume":"61","author":"Walsh","year":"2013","journal-title":"American Journal of Kidney Diseases"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0033|cit33","first-page":"27","article-title":"Aspreva lupus management study maintenance results [abstract no: CS12.6]","volume":"19","author":"Wofsy","year":"2010","journal-title":"Lupus"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub4-BIB0034|cit34","first-page":"493","article-title":"Mycophenolate mofetil compared with intravenous cyclophosphamide in the treatment of lupus nephritis: predictors of response [abstract no: SAT0188]","volume":"67","author":"Wofsy","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1186\/ar3738","article-title":"Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial","volume":"14","author":"Ginzler","year":"2012","journal-title":"Arthritis Research & Therapy"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0036|cit36","first-page":"4362","article-title":"Speed of remission with the use of voclosporin, MMF and low dose steroids: results of a global lupus nephritis study [abstract no: 5L]","volume":"68","author":"Dooley","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"A2","DOI":"10.1053\/j.ajkd.2017.03.008","article-title":"Treatment of active lupus nephritis with voclosporin: 48 week data from the AURA-LV study [abstract no: 4]","volume":"69","author":"Parikh","year":"2017","journal-title":"American Journal of Kidney Diseases"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0038|cit38","first-page":"2B","article-title":"AURA-LV: successful treatment of active lupus nephritis with voclosporin [abstract no: HI-OR05]","volume":"27","author":"Pendergraft","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000421703","article-title":"Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis","volume":"99","author":"Balletta","year":"1992","journal-title":"Contributions to Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1681\/ASN.2007121272","article-title":"Successful treatment of class V+IV lupus nephritis with multi-target therapy","volume":"19","author":"Bao","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub4-BIB0041|cit41","first-page":"48a","article-title":"Successful treatment of class V+IV lupus nephritis with multi-target immunosuppressive therapy [abstract no: SA-FC060]","volume":"18","author":"Bao","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0022-3476(82)80203-5","article-title":"Pulse methylprednisolone therapy in diffuse proliferative lupus nephritis","volume":"101","author":"Barron","year":"1982","journal-title":"Journal of Pediatrics"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1097\/00045391-199512000-00005","article-title":"Misoprostol and prednisone treatment of lupus nephritis","volume":"2","author":"Belmont","year":"1995","journal-title":"American Journal of Therapeutics"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0044|cit44","first-page":"156","article-title":"Study design and baseline patient characteristics of BELONG, the randomized double-blind, placebo-controlled phase III trial of ocrelizumab, a humanized anti-CD20 antibody, in lupus nephritis [abstract no: PO2.E20]","volume":"19","author":"Mysler","year":"2010","journal-title":"Lupus"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0046|cit46","first-page":"1455","article-title":"Efficacy and safety of ocrelizumab, a humanized antiCD20 antibody, in patients with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III BELONG Study [abstract]","volume":"62","author":"Mysler","year":"2010","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"e000226","DOI":"10.1136\/lupus-2017-000226","article-title":"Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon-gamma monoclonal antibody, in SLE subjects without or with lupus nephritis","volume":"4","author":"Boedigheimer","year":"2017","journal-title":"Lupus Science & Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0048|cit48","first-page":"140A","article-title":"Comparative study of pulse treatment with cyclophosphamide or immunoglobulin to sustain the remission of lupus nephritis [abstract]","volume":"9","author":"Boletis","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9178","key":"10.1002\/14651858.CD002922.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S0140-6736(99)01575-5","article-title":"Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis","volume":"354","author":"Boletis","year":"1999","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0050|cit50","first-page":"411","article-title":"Prognostic indicators supporting use of short courses of pulse immunosuppression for severe lupus nephritis (LN) [abstract no: 130]","volume":"6","author":"Austin","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8822","key":"10.1002\/14651858.CD002922.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1159\/000180176","article-title":"Comparison of azathioprine, prednisone, and heparin alone or combined in treating lupus nephritis","volume":"10","author":"Cade","year":"1973","journal-title":"Nephron"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0054|cit54","first-page":"195A","article-title":"Prolonged follow-up of patients with diffuse proliferative lupus nephritis (DPLN) treated with prednisolone and mycophenolate mofetil (MMF) [abstract no: A1010]","volume":"12","author":"Chan","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0057|cit55","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0961203308091285","article-title":"Mycophenolate mofetil in the treatment of lupus nephritis: 7 years on","volume":"17","author":"Chan","year":"2008","journal-title":"Lupus"},{"issue":"16","key":"10.1002\/14651858.CD002922.pub4-BIB0055|cit56","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1056\/NEJM200010193431604","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group","volume":"343","author":"Chan","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0056|cit57","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1681\/ASN.2004080686","article-title":"Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis","volume":"16","author":"Chan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1056\/NEJM200102013440513","article-title":"Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis","volume":"344","author":"Karassa","year":"2001","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0059|cit59","unstructured":"Chen W Liu Q Chen W Fu P Liao Y Zhang J A prospective multicenter randomized trial of treatment of active lupus nephritis with tacrolimus versus cyclophosphamide\/azathioprine in Chinese adults [abstract no: SU248] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/0961203312442259","article-title":"Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: a multicenter randomized clinical trial","volume":"21","author":"Chen","year":"2012","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1053\/j.ajkd.2010.08.036","article-title":"Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial","volume":"57","author":"Chen","year":"2011","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0062|cit62","first-page":"171","article-title":"Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: a pilot study","volume":"125","author":"Clark","year":"1981","journal-title":"Canadian Medical Association Journal"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0063|cit63","first-page":"928","article-title":"Elective plasmapheresis in S.L.E. nephritis: pilot for a controlled prospective study [abstract]","volume":"16","author":"Clark","year":"1979","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0064|cit64","first-page":"353","article-title":"Long-term plasma exchange in patients with systemic lupus erythematosus and diffuse proliferative glomerulonephritis","volume":"5","author":"Clark","year":"1984","journal-title":"Plasma Therapy & Transfusion Technology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0065|cit65","first-page":"424","article-title":"Chronic plasma exchange in SLE nephritis [abstract]","volume":"24","author":"Clark","year":"1983","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0066|cit66","first-page":"629","article-title":"Chronic plasma exchange in systemic lupus erythematosus nephritis","volume":"20","author":"Clark","year":"1983","journal-title":"Proceedings of the European Dialysis & Transplant Association"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0067|cit67","first-page":"161","article-title":"A controlled trial of chronic plasma exchange therapy in S.L.E. nephritis [abstract]","volume":"25","author":"Clark","year":"1984","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0068|cit68","first-page":"147","article-title":"Controlled trial of chronic plasma exchange therapy in SLE nephritis [abstract]","volume":"21","author":"Clark","year":"1982","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0069|cit69","unstructured":"Linton AL Williams W Cattran D Lindsay R Clark W Controlled trial of chronic plasma exchange in SLE nephritis [abstract] Australasian Society of Nephrology.19th Annual Scientific Meeting. 2nd Asian Congress of Nephrology; 1983 Feb 14-18; Melbourne, Australia 1983 48"},{"issue":"Sept Program &","key":"10.1002\/14651858.CD002922.pub4-BIB0070|cit70","first-page":"15A","article-title":"Maintenance therapy for proliferative forms of lupus nephritis: a randomized clinical trial comparing quarterly intravenous cyclophosphamide (IVCY) versus oral mycophenolate mofetil (MMF) or azathioprine (AZA) [abstract no: F-FC069]","volume":"13","author":"Contreras","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0071|cit71","first-page":"38A","article-title":"Lupus nephritis: sequential therapy with short-term intravenous cyclophosphamide followed by maintenance oral mycophenolate mofetil or oral azathioprine is more efficacious and safer than long-term intravenous cyclophosphamide [abstract no: SA-FC173]","volume":"14","author":"Contreras","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0073|cit73","first-page":"99A","article-title":"Immunosupressive therapy for proliferative lupus nephritis: preliminary report of a prospective, randomized clinical trial with mycophenolate mofetil (MMF) [abstract]","volume":"10","author":"Contreras","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1177\/096120330501400107","article-title":"Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide","volume":"14","author":"Contreras","year":"2005","journal-title":"Lupus"},{"key":"#cr-split#-10.1002\/14651858.CD002922.pub4-BIB0075|cit75.1","unstructured":"Dostal C Tesar V Rysava R Rovensky J Rychlik I Hrneio Z Cyclofa-Lune (2002) lupus nephritis - randomized controlled multicentric therapeutic comparative study with cyclosporin A versus cyclophosphamide: running evaluation [abstract no: THU0390] Annual European Congress of Rheumatology EULAR 2004"},{"key":"#cr-split#-10.1002\/14651858.CD002922.pub4-BIB0075|cit75.2","doi-asserted-by":"crossref","unstructured":"2004 Jun 9-12, Berlin (Germany) 2004","DOI":"10.1016\/S1359-6128(04)00606-8"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0076|cit76","first-page":"S256","article-title":"Extended follow-up of a investigator-initiated trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or cyclosporine [abstract no: 596]","volume":"65","author":"Zavada","year":"2013","journal-title":"Arthritis and Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/0961203310371155","article-title":"Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study","volume":"19","author":"Zavada","year":"2010","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0961203313511555","article-title":"Extended follow-up of the CYCLOFA-LUNE trial comparing two sequential induction and maintenance treatment regimens for proliferative lupus nephritis based either on cyclophosphamide or on cyclosporine A","volume":"23","author":"Zavada","year":"2014","journal-title":"Lupus"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0080|cit80","first-page":"204","article-title":"Immunosuppressive therapy of lupus nephritis [abstract]","volume":"27","author":"Austin","year":"1985","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/0002-9343(83)90338-8","article-title":"Prognostic factors in lupus nephritis. Contribution of renal histologic data","volume":"75","author":"Austin","year":"1983","journal-title":"American Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-99-1-1","article-title":"Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up","volume":"99","author":"Carette","year":"1983","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"606","DOI":"10.7326\/0003-4819-83-5-606","article-title":"Cyclophosphamide or azathioprine in lupus glomerulonephritis. A controlled trial: results at 28 months","volume":"83","author":"Decker","year":"1975","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-91-4-587","article-title":"NIH conference. Systemic lupus erythematosus: evolving concepts","volume":"91","author":"Decker","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD002922.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"728","DOI":"10.7326\/0003-4819-96-6-728","article-title":"Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis","volume":"96","author":"Dinant","year":"1982","journal-title":"Annals of Internal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780340803","article-title":"Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only","volume":"34","author":"Steinberg","year":"1991","journal-title":"Arthritis & Rheumatology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0087|cit87","first-page":"499A","article-title":"A clinical research of the effect of leflunomide as an induction treatment for proliferative lupus nephritis [abstract no: FR-PO593]","volume":"27","author":"Deng","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3-4","key":"10.1002\/14651858.CD002922.pub4-BIB0088|cit88","first-page":"168","article-title":"Prospective multicentre trial on the short- term effects of plasma exchange versus cytotoxic drugs in corticosteroid-resistant lupus nephritis","volume":"33","author":"Derksen","year":"1988","journal-title":"Netherlands Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.1780170511","article-title":"Further observations on the treatment of lupus nephritis with prednisone and combined prednisone and azathioprine","volume":"17","author":"Donadio","year":"1974","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"829","DOI":"10.7326\/0003-4819-77-6-829","article-title":"Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine","volume":"77","author":"Donadio","year":"1972","journal-title":"Annals of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0091|cit91","first-page":"465","article-title":"Long-term treatment of diffuse proliferative lupus nephritis (DPLN) with prednisone and combined prednisone and cyclophosphamide [abstract]","volume":"12","author":"Donadio","year":"1977","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0092|cit92","first-page":"484","article-title":"Progressive lupus glomerulonephritis. Treatment with prednisone and combined prednisone and cyclophosphamide","volume":"51","author":"Donadio","year":"1976","journal-title":"Mayo Clinic Proceedings"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0094|cit94","first-page":"307","article-title":"Therapy of lupus nephritis. A two-year prospective study","volume":"145","author":"Doria","year":"1994","journal-title":"Annales de Medecine Interne"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0095|cit95","first-page":"A57","article-title":"Azathioprine and cyclophosphamide in treatment of patients with diffuse proliferative lupus nephritis - a randomized controlled study [abstract]","volume":"16","author":"Dyadyk","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub4-BIB0096|cit96","first-page":"467","article-title":"Azathioprine and cyclophosphamide in diffuse proliferative lupus nephritis treatment - a randomized controlled study [abstract no: SAT0125]","volume":"66","author":"Dyadyk","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0097|cit97","unstructured":"Abd-ELHady El-Sehemy M Al-Saaran AM Al-Saeed Baddour NM El-Sayed Moez P Adam AG Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 48"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0098|cit98","unstructured":"Abd-ELHady El-Sehemy M Al-Saaran AM Al-Saeed Baddour NM El-Sayed Moez P Gaber Adam A Cyclosporine but not cyclophosphamide is a rescue therapy in resistant lupus nephritis even in class iv proliferative GN [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 48"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0099|cit99","first-page":"122A","article-title":"Prospective comparative study between azathioprine \"AZA\", cyclophosphamide \"CYP\", cyclosporine \"CsA\" and mycophenolate mofetil \"MMF\" in the treatment of lupus nephritis: is CYP still the preferred therapy against the new-comer MMF. AZA: an old drug with still a great potential? [abstract no: F-PO258]","volume":"15","author":"Adam","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0100|cit100","first-page":"39","article-title":"Comparative clinical prospective therapeutic study between cyclophosphamide, cyclosporine and azathioprine in the treatment of lupus nephritis","volume":"13","author":"El-Sehemy","year":"2006","journal-title":"Egyptian Journal of Immunology\/Egyptian Association of Immunologists"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10157-010-0270-7","article-title":"Is mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?","volume":"14","author":"Shafey","year":"2010","journal-title":"Clinical & Experimental Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0102|cit102","first-page":"122A","article-title":"Open randomized trial comparing mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis (LN) [abstract no: F-PO257]","volume":"15","author":"Flores-Suarez","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0103|cit103","unstructured":"Flores-Suarez LF Villa AR Preliminary results of an open randomised clinical trial comparing mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IV-CYC) as induction therapy for severe lupus nephritis [abstract no: THU0413] Annual European Congress of Rheumatology EULAR 2004; 2004 Jun 9-12, Berlin, Germany 2004"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/art.1780160204","article-title":"Cyclophosphamide therapy in systemic lupus erythematosus and polymyositis","volume":"16","author":"Fries","year":"1973","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/rheumatology\/37.2.217","article-title":"Clinical efficacy of cyclosporin A neoral in the treatment of paediatric lupus nephritis with heavy proteinuria","volume":"37","author":"Fu","year":"1998","journal-title":"British Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1046\/j.1365-2125.1997.00634.x","article-title":"Cyclosporin pharmacokinetics following administration of capsules and Neoral in paediatric patients with lupus nephritis","volume":"44","author":"Fu","year":"1997","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0108|cit107","first-page":"S962","article-title":"Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II\/III study [abstract]","volume":"63","author":"Furie","year":"2014","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0107|cit108","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1002\/art.34624","article-title":"Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions","volume":"64","author":"Wofsy","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/art.37940","article-title":"Comparison of alternative primary outcome measures for use in lupus nephritis clinical trials","volume":"65","author":"Wofsy","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/1529-0131(197607\/08)19:4<693::AID-ART1780190406>3.0.CO;2-2","article-title":"Prednisone and azathioprine compared to prednisone plus low-dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis","volume":"19","author":"Ginzler","year":"1976","journal-title":"Arthritis & Rheumatism"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0112|cit112","first-page":"38A","article-title":"Multicenter controlled trial of mycophenolate mofetil (MMF) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN) [abstract no: SA-FC171]","volume":"14","author":"Appel","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ncpneph0184","article-title":"Induction therapy for active lupus nephritis: mycophenolate mofetil versus cyclophosphamide","volume":"2","author":"Burchardi","year":"2006","journal-title":"Nature Clinical Practice Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ncprheum0217","article-title":"Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide","volume":"2","author":"Elliott","year":"2006","journal-title":"Nature Clinical Practice Rheumatology"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc053503","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide in lupus nephritis","volume":"354","author":"Karassa","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0117|cit117","first-page":"8A","article-title":"Mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) for severe lupus nephritis (LN): subgroup analysis of patients with membranous nephropathy (SLE-V) [abstract no: TH-FC036]","volume":"16","author":"Radhakrishnan","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD002922.pub4-BIB0118|cit118","first-page":"779A","article-title":"Lupus membranous nephropathy IV cyclophosphamide (IVC) vs. mycophenolate mofetil (MMF) [abstract no: SA-PO2951]","volume":"19","author":"Radhakrishnan","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0119|cit119","first-page":"55","article-title":"Should therapy go beyond the control of immediate injury? Biomarkers of the vasculature and their association with longitudinal assessments in the induction phase of a randomized multicenter trial comparing mycophenolate mofetil and intravenous cyclophosphamide [abstract no: PO1.B.31]","volume":"19","author":"Robert","year":"2010","journal-title":"Lupus"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1002\/art.10142","article-title":"Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies","volume":"46","author":"Illei","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0123|cit123","first-page":"350","article-title":"Cyclophosphamide versus azathioprine\/methylprednisolone: long-term follow-up of the first Dutch lupus nephritis study [abstract]","volume":"20","author":"Arends","year":"2011","journal-title":"Lupus"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/annrheumdis-2011-200384","article-title":"Long-term follow-up of a randomised controlled trial of azathioprine\/methylprednisolone versus cyclophosphamide in patients with proliferative lupus nephritis","volume":"71","author":"Arends","year":"2012","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/ndt\/gfm555","article-title":"Interobserver agreement of scoring of histopathological characteristics and classification of lupus nephritis","volume":"23","author":"Grootscholten","year":"2008","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/art.22449","article-title":"Treatment with cyclophosphamide delays the progression of chronic lesions more effectively than does treatment with azathioprine plus methylprednisolone in patients with proliferative lupus nephritis","volume":"56","author":"Grootscholten","year":"2007","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0127|cit127","unstructured":"Grootscholten C Bijl M Ligtenberg G Hagen EC van den Wall Bake AW de Glas-Vos JW Is azathioprine an alternative for cyclophosphamide in the treatment of patients with proliferative lupus nephritis? Two year results of the Dutch Lupus Nephritis Study [abstract no: OP0176] Annual European Congress of Rheumatology EULAR; 2004 Jun 9-12; Berlin (Germany) 2004"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1136\/ard.2006.065425","article-title":"A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine\/methylprednisolone","volume":"66","author":"Grootscholten","year":"2007","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney International"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0130|cit130","first-page":"54A","article-title":"Randomized controlled trial comparing cyclophosphamide pulse therapy with azathioprine\/methylprednisolone in proliferative lupus nephritis [abstract no: SU-FC047]","volume":"15","author":"Grootscholten","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0131|cit131","first-page":"1699","article-title":"Health-related quality of life and treatment burden in patients with proliferative lupus nephritis treated with cyclophosphamide or azathioprine\/methylprednisolone in a randomized controlled trial","volume":"34","author":"Grootscholten","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0132|cit132","first-page":"14A","article-title":"Cyclophosphamide pulse therapy versus azathioprine and methylprednisolone pulses in proliferative lupus nephritis: first results of a randomized, prospective multicenter study [abstract no: F-FC067]","volume":"13","author":"Ligtenberg","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"597","DOI":"10.7326\/0003-4819-83-5-597","article-title":"Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus. Report of a prospective controlled trial in 24 patients","volume":"83","author":"Hahn","year":"1975","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub4-BIB0134|cit134","first-page":"vi276","article-title":"A preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis [abstract no: SaP131]","volume":"22","author":"Hong","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0143|cit136","unstructured":"Houssiau FA The 10-year followup of the Euro-Lupus Nephritis Trial (ELNT), a randomized prospective trial comparing low-dose (LD) versus high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment of proliferative lupus nephritis [abstract no: 2060] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CA) 2008"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0136|cit137","unstructured":"Houssiau FA Cosyns J Cervera R The Euro-Lupus Nephritis Trial: 5-year follow-up [abstract no: OP0054] Annual European Congress of Rheumatology EULAR; 2003 June 18-21; Lisbon (Portugal) 2003"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub4-BIB0137|cit138","first-page":"64","article-title":"Long term outcome of patients randomized in the Euro-Lupus Nephritis Trial: further evidence that a low-dose IV cyclophosphamide induction regimen achieves good results [abstract no: OP0034]","volume":"65","author":"Houssiau","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0138|cit139","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0139|cit140","unstructured":"Houssiau FA Vasconcelos C D'Cruz D Sebastiani GD de Ramon Garrido E Danieli MG Early response to immunosuppressive therapy predicts good long-term renal outcome in lupus nephritis: lessons from the Euro-Lupus Nephritis trial (ELNT) [abstract no: 67] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0140|cit141","doi-asserted-by":"crossref","unstructured":"Houssiau FA Vasconcelos C D'Cruz D Sebastiani GD de Ramon Garrido E Danieli MG Early response to immunosuppressive therapy predicts good long-term renal outcome in proliferative lupus glomerulonephritis: lessons from the Euro-Lupus Nephritis Trial [abstract no: OP0174] Annual European Congress of Rheumatology EULAR; 2004 Jun 9-12; Berlin (Germany) 2004","DOI":"10.1002\/art.20666"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0141|cit142","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.1002\/art.20666","article-title":"Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial","volume":"50","author":"Houssiau","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0142|cit143","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/annrheumdis-2013-eular.528","article-title":"A randomized controlled study of laquinimod in active lupus nephritis patients in combination with standard of care [abstract no: LB0003]","volume":"72","author":"Jayne","year":"2013","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4103\/1319-2442.185233","article-title":"Mycophenolate mofetil versus azathioprine for maintenance treatment of lupus nephritis","volume":"27","author":"Kaballo","year":"2016","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1177\/0961203317739131","article-title":"Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial","volume":"27","author":"Kamanamool","year":"2017","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0147|cit147","unstructured":"Sumethkul V Comparison between tacrolimus (TAC) and mycophenolate mofetil (MMF) for induction of remission in lupus nephritis clinicaltrials.gov\/ct2\/show\/NCT01580865"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub4-BIB0149|cit148","first-page":"731A","article-title":"The value of a partial remission in severe lupus nephritis [abstract no: SA-PO743]","volume":"17","author":"Chen","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0148|cit149","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2215\/CJN.03280807","article-title":"Value of a complete or partial remission in severe lupus nephritis","volume":"3","author":"Chen","year":"2008","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0150|cit150","first-page":"301","article-title":"Treatment protocols of the lupus nephritis collaborative study of plasmapheresis in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"337","author":"Clough","year":"1990","journal-title":"Progress in Clinical & Biological Research"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0152|cit152","first-page":"266A","article-title":"Complete remission rate and outcome in severe lupus nephritis: the impact of baseline serum creatinine [abstract no: TH-PO769]","volume":"26","author":"Korbet","year":"2015","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(92)90030-4","article-title":"Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study","volume":"13","author":"Lachin","year":"1992","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7326\/0003-4819-116-2-114","article-title":"Progression and remission of renal disease in the Lupus Nephritis Collaborative Study. Results of treatment with prednisone and short-term oral cyclophosphamide","volume":"116","author":"Levey","year":"1992","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0155|cit155","first-page":"208","article-title":"Primary outcomes in the controlled trial of plasmapheresis therapy (PPT) in severe lupus nephritis [abstract]","volume":"31","author":"Lewis","year":"1987","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0157|cit156","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/jca.2920070314","article-title":"Plasmapheresis therapy is ineffective in SLE. Lupus Nephritis Collaborative Study Group","volume":"7","author":"Lewis","year":"1992","journal-title":"Journal of Clinical Apheresis"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub4-BIB0156|cit157","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1056\/NEJM199205213262101","article-title":"A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"326","author":"Lewis","year":"1992","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0961203310385267","article-title":"The prognosis of severe lupus nephritis based on the Modification of Diet in Renal Disease (MDRD) study estimated glomerular filtration rate","volume":"20","author":"Patel","year":"2011","journal-title":"Lupus"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0159|cit159","first-page":"230","article-title":"Plasmapheresis (PP) does not enhance the susceptibility to infections in immunosuppressed patients with lupus nephritis [abstract]","volume":"35","author":"Pohl","year":"1989","journal-title":"Kidney International"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.7326\/0003-4819-114-11-924","article-title":"Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group","volume":"114","author":"Pohl","year":"1991","journal-title":"Annals of Internal Medicine"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0161|cit161","first-page":"247","article-title":"Rituximab monotherapy is an effective induction therapy in proliferative lupus nephritis: a pilot study [abstract no: THU0223]","volume":"68","author":"Li","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/rheumatology\/kep124","article-title":"Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?","volume":"48","author":"Li","year":"2009","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1093\/ndt\/gfr484","article-title":"Mycophenolate mofetil or tacrolimus compared with intravenous cyclophosphamide in the induction treatment for active lupus nephritis","volume":"27","author":"Li","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0164|cit164","first-page":"391A","article-title":"Induction therapies for proliferative lupus nephritis: mycophenolate mofetil, tacrolimus and intravenous cyclophosphamide [abstract]","volume":"20","author":"Li","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0165|cit165","unstructured":"Liou C Ni Z Qian J Lin A Zhang W Fang W Treatment of lupus nephritis type_and_with leflunomide: A two year prospective sequential therapies [abstract no: M-PO-1081] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 349"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/M14-1030","article-title":"Multitarget therapy for induction treatment of lupus nephritis: a randomized trial.[Summary for patients in Ann Intern Med. 2015 Jan 6;162(1):I24; PMID: 25383607]","volume":"162","author":"Liu","year":"2015","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0167|cit167","unstructured":"Loo CY Kong NCT Shahrir M Suriani A Halim AG Rozita M Plasmapheresis versus immunoadsorption in severe lupus nephritis (LN) [abstract no: M-PO-0967] 4th World Congress of Nephrology.19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 319"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.transci.2010.10.003","article-title":"Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis","volume":"43","author":"Loo","year":"2010","journal-title":"Transfusion & Apheresis Science"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0169|cit169","first-page":"S476","article-title":"Treatment of type iv lupus nephritis (LN) - comparison of 2 triple therapy regimens: cyclosporin a (CSA), prednisolone (PRED), azathioprine (AZA) vs. oral cyclophosphamide (POCP), prednisolone, azathioprine [abstract no: P1613]","volume":"3","author":"Lui","year":"1997","journal-title":"Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub4-BIB0170|cit170","first-page":"573A","article-title":"Protocol for the Lupus Nephritis Assessment with rituximab (LUNAR) Study [abstract no: F-PO1121]","volume":"17","author":"Appel","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0171|cit171","first-page":"15","article-title":"Efficacy and safety of rituximab (RTX) in patients (Pts) with proliferative lupus nephritis (LN): results from randomized, double-blind phase III LUNAR study at week 52 [abstract no: CS6.6]","volume":"19","author":"Furie","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0172|cit172","first-page":"549","article-title":"Efficacy and safety of rituximab in patients with proliferative lupus nephritis: results from the randomized, double-blind phase III LUNAR study [abstract no: SAT0185]","volume":"69","author":"Furie","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0173|cit173","unstructured":"Furie R Looney RJ Rovin B Latinis KM Appel G Sanchez-Guerrero J Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract no: 1149] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0174|cit174","first-page":"157","article-title":"Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial [abstract no: PO2.E.22]","volume":"19","author":"Furie","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0175|cit175","first-page":"550","article-title":"Effect of rituximab (RTX) on anti -double-stranded DNA antibody and c3 levels and relationship to response: results from the LUNAR trial [abstract no: SAT0186]","volume":"69","author":"Furie","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0176|cit176","unstructured":"Furie R Rovin B Appel G Kamen DL Fervenza FC Spindler A Effect of rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: results from the LUNAR trial [abstract no: 271] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0177|cit177","first-page":"253","article-title":"Trial design and baseline characteristics of patients in the randomized double-blind, placebo-controlled phase III lupus nephritis assessment with rituximab study (LUNAR) [abstract no: THU-0242]","volume":"68","author":"Furie","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0178|cit178","unstructured":"Rovin B Appel G Furie R Fervenza F Guerrero JS Lenz O Trial design and baseline characteristics of patients in the randomized double-blind, placebo-controlled phase III LUpus Nephritis Assessment with Rituximab study (LUNAR) [abstract no: M353] World Congress of Nephrology; 2009 May 22-26; Milan, Italy 2009"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0179|cit179","first-page":"406A","article-title":"Effect of Rituximab (RTX) on anti-dsDNA and C3 levels and relationship to response: Results from the LUNAR Trial [abstract no: F-PO1281]","volume":"20","author":"Rovin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0180|cit180","first-page":"77A","article-title":"Efficacy and safety of rituximab (RTX) in subjects with proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study [abstract no: SA-FC332]","volume":"20","author":"Rovin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis & Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0183|cit183","first-page":"552","article-title":"Longterm renal outcome in lupus nephritis patients can be predicted by the kinetics of proteinuria drop in response to therapy: data from the MAINTAIN NEPHRITIS trial [abstract no: SAT0193]","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0184|cit184","unstructured":"Houssiau FA D'Cruz DP Sangle SR Remy P Vasconcelos C De Ramon Garrido E Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis: results of a randomized trial (MAINTAIN) [abstract no: 1150] ACR\/ARHP Annual Scientific Meeting; 2009 Oct 17-21; Philadelphia (PA) 2009"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1093\/ndt\/gfr553","article-title":"Repeat kidney biopsies fail to detect differences between azathioprine and mycophenolate mofetil maintenance therapy for lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"27","author":"Stoenoiu","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0186|cit186","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"e000123","DOI":"10.1136\/lupus-2015-000123","article-title":"A proteinuria cut-off level of 0.7 g\/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial","volume":"2","author":"Tamirou","year":"2015","journal-title":"Lupus Science & Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0188|cit188","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00296-018-3995-3","article-title":"Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study","volume":"38","author":"Mehra","year":"2018","journal-title":"Rheumatology International"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0189|cit189","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.4103\/1319-2442.215147","article-title":"Mycophenolate mofetil or cyclophosphamide in Indian patients with lupus nephritis: Which is better? A single-center experience","volume":"28","author":"Mendonca","year":"2017","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0190|cit190","first-page":"935","article-title":"Comparison of high and low dose of cyclophosphamide in lupus nephritis patients: a long-term randomized controlled trial","volume":"22","author":"Mitwalli","year":"2011","journal-title":"Saudi Journal of Kidney Diseases & Transplantation"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0191|cit191","unstructured":"Mok C Ying K Tong K Siu Y To C Yim C Mycophenolate mofetil versus tacrolimus for active lupus nephritis: an extended observation of a randomized controlled trial [abstract no: 1073] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CA) 2008"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0201|cit192","first-page":"923","article-title":"Factors determining response in patients with acute lupus nephritis treated with glucocorticoids and mycophenolate mofetil (MMF) [abstract]","volume":"60","author":"Mok","year":"2009","journal-title":"Arthritis and Rheumatism"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0192|cit193","first-page":"988","article-title":"Factors associated with renal remission, relapse and long-term renal function decline in lupusnephritis treated with combined prednisolone and mycophenolate mofetil (MMF) or tacrolimus(TAC) [abstract no: 988]","volume":"67","author":"Mok","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0193|cit194","first-page":"S258","article-title":"Factors associated with long-term renal function deterioration in lupus nephritis treated initially with combined prednisolone and mycophenolate mofetil (MMF) or tacrolimus (TAC) [abstract no: 600]","volume":"65","author":"Mok","year":"2013","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0194|cit195","first-page":"555","article-title":"Risk of renal flares and decline in renal function in patients with active lupus nephritis treated with mycophenolate mofetil (MMF) [abstract no: SAT0202]","volume":"69","author":"Mok","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0195|cit196","first-page":"477","article-title":"Risk of renal flares and decline in renal function in patients with active lupus nephritis treated with mycophenolate mofetil (MMF) [abstract]","volume":"60","author":"Mok","year":"2010","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0196|cit197","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1136\/annrheumdis-2014-206456","article-title":"Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up","volume":"75","author":"Mok","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0197|cit198","first-page":"155","article-title":"Factors determining response in patients with active lupus nephritis treated with glucocorticoids and mycophenolate mofetil (MMF) [abstract no: PO2.E.17]","volume":"19","author":"Mok","year":"2010","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0198|cit199","first-page":"75","article-title":"Tacrolimus (TAC) versus mycophenolate mofetil (MMF) for the treatment of membranous lupus nephritis: a randomized controlled trial [abstract no: OP0069]","volume":"69","author":"Mok","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0199|cit200","first-page":"16","article-title":"Tacrolimus (Tac) versus mycophenolate mofetil (MMF) for the treatment of membranous lupus nephritis: a randomized controlled trial [abstract no: CS6.8]","volume":"19","author":"Mok","year":"2010","journal-title":"Lupus"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0200|cit201","first-page":"246","article-title":"Mycophenolate mofetil versus tacrolimus for active lupus nephritis: an extended observation of a randomized controlled trial [abstract no: THU0220]","volume":"68","author":"Mok","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0202|cit202","unstructured":"Doria A Ponticelli C Mosca M Ferraccioli GF Moroni G Todesco S A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0203|cit203","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0204|cit204","first-page":"121A","article-title":"A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract no: F-PO255]","volume":"15","author":"Moroni","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0205|cit205","unstructured":"Moroni G Doria A Mosca M Ferraccioli G Todesco S Schena P A randomized trial comparing cyclosporine versus azathioprine for maintenance therapy in diffuse lupus nephritis [abstract no: MO30] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon, Portugal 2004 224"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0206|cit206","unstructured":"Mosca M Doria A Moroni G Ferrara R Todesco S Ponticelli C Induction therapy with oral cyclophosphamide in lupus nephritis [abstract no: THU0166] Annual European Congress of Rheumatology EULAR; 2002 June 12-15; Stockholm, Sweden 2002"},{"issue":"Suppl II","key":"10.1002\/14651858.CD002922.pub4-BIB0207|cit207","first-page":"349","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide in treatment of lupus nephritis [abstract no: FRI0201]","volume":"67","author":"Mulic-Bacic","year":"2008","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0208|cit208","unstructured":"Jayne D Amoura Z Zeher M Boletis J Hiepe F Enteric-coated mycophenolate sodium in patients with lupus nephritis: rationale and design of a multicenter randomized steroid-sparing trial [abstract no: M-PO-1114] 4th World Congress of Nephrology. 19th International Congress of the International Society of Nephrology (ISN); 2007 Apr 21-25; Rio de Janeiro, Brazil 2007 357"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0209|cit209","first-page":"626A","article-title":"Enteric-coated mycophenolate sodium (ED-MPS) for the treatment of lupus nephritis - MyLupus study [abstract no: SA-PO2253]","volume":"21","author":"Jayne","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD002922.pub4-BIB0210|cit210","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0211|cit211","first-page":"559","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) in combination with two corticosteroid regimens for the treatment of lupus nephritis flare - results of the MYLUPUS study [abstract no: SAT0213]","volume":"69","author":"Zeher","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0212|cit212","first-page":"250","article-title":"Enteric coated mycophenolate sodium (EC-MPS) treatment of lupus nephritis flare - interim results from a multicenter, randomized trial [abstract no: THU0234]","volume":"68","author":"Zeher","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0213|cit213","doi-asserted-by":"crossref","first-page":"108","DOI":"10.5414\/CNP57108","article-title":"Comparative effects of plasmapheresis and intravenous cyclophosphamide on urinary podocyte excretion in patients with proliferative lupus nephritis","volume":"57","author":"Nakamura","year":"2002","journal-title":"Clinical Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0215|cit214","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1440-1797.2005.00444.x","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0214|cit215","first-page":"A121","article-title":"Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis [abstract no: FC30041]","volume":"10","author":"Ong","year":"2005","journal-title":"Nephrology"},{"issue":"5 Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0216|cit216","first-page":"S9","article-title":"Comparison of tacrolimus-azathioprine combination versus cyclophosphamide for induction treatment of proliferative lupus nephritis [abstract no: OC014]","volume":"12","author":"Pal","year":"2017","journal-title":"Indian Journal of Rheumatology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD002922.pub4-BIB0217|cit217","first-page":"48A","article-title":"Randomized controlled trial of low dose intravenous cyclophosphamide versus oral mycophenolate mofetil in treatment of lupus nephritis [abstract no: FR-OR053]","volume":"24","author":"Goyal","year":"2013","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0218|cit218","first-page":"iii28","article-title":"Randomized controlled trial of low-dose intravenous cyclophosphamide versus oral mycophenolate mofetil in treatment of lupus nephritis [abstract]","volume":"29","author":"Rathi","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0219|cit219","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.318","article-title":"Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis","volume":"89","author":"Rathi","year":"2016","journal-title":"Kidney International"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0220|cit220","first-page":"2941","article-title":"Outcomes in lupus nephritis patients previously randomized to receive either low dose cyclophosphamide versus oral mycophenolate mofetil on azathioprine maintenance [abstract no: 2941]","volume":"67","author":"Rathi","year":"2015","journal-title":"Arthritis & Rheumatology"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0221|cit221","first-page":"S1239","article-title":"A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis [abstract no: 2835]","volume":"66","author":"Aranow","year":"2014","journal-title":"Arthritis & Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0222|cit222","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.1002\/art.39722","article-title":"A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis","volume":"68","author":"Rovin","year":"2016","journal-title":"Arthritis & Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0223|cit223","first-page":"204A","article-title":"Efficacy and safety of sirukumab in patients with active lupus nephritis: results from a phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study [abstract no: TH-PO426]","volume":"25","author":"Rovin","year":"2014","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0224|cit224","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11255-007-9325-4","article-title":"A comparative study of two intensified pulse cyclophosphamide remission-inducing regimens for diffuse proliferative lupus nephritis: an Egyptian experience","volume":"41","author":"Sabry","year":"2009","journal-title":"International Urology & Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD002922.pub4-BIB0225|cit225","first-page":"vi28","article-title":"A comparative study of two intensified pulse cyclophosphamide remission-inducing regimen for diffuse proliferative lupus nephritis: an Egyptian experience [abstract no: FP036]","volume":"22","author":"Sabry","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0226|cit226","first-page":"500A","article-title":"Effect of cyclophosphamide versus mycophenolate mofetil in induction therapy of lupus nephritis in Nepalese population [abstract no: FR-PO598]","volume":"27","author":"Sedhain","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0227|cit227","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/096120339400300209","article-title":"A controlled trial of pulse cyclophosphamide versus pulse methylprednisolone in severe lupus nephritis","volume":"3","author":"Sesso","year":"1994","journal-title":"Lupus"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0228|cit228","first-page":"286","article-title":"Pulse cyclophosphamide (CY) versus pulse methylprednisolone (MP) in severe lupus nephritis [abstract no: 97P]","volume":"4","author":"Sesso","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0229|cit229","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40697-014-0030-9","article-title":"The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial","volume":"1","author":"Galbraith","year":"2014","journal-title":"Canadian Journal of Kidney Health & Disease"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0230|cit230","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-75-2-165","article-title":"Cyclophosphamide in lupus nephritis: a controlled trial","volume":"75","author":"Steinberg","year":"1971","journal-title":"Annals of Internal Medicine"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0231|cit231","first-page":"21572","article-title":"Efficacy and safety of cyclophosphamide combined with mycophenolate mofetil for induction treatment of class IV lupus nephritis","volume":"8","author":"Sun","year":"2015","journal-title":"International Journal of Clinical & Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0232|cit232","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/(SICI)1098-1101(1998)13:4<163::AID-JCA4>3.0.CO;2-1","article-title":"Randomized controlled trial of pulse\/synchronization cyclophosphamide\/apheresis for proliferative lupus nephritis","volume":"13","author":"Wallace","year":"1998","journal-title":"Journal of Clinical Apheresis"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0233|cit233","doi-asserted-by":"crossref","first-page":"iii510","DOI":"10.1093\/ndt\/gfx165.MP230","article-title":"Effect of cyclophosphamide and mycophenolate mofetil on lymphocyte subsets in patients with active lupus nephritis effect of cyclophosphamide and mycophenolate mofetil on lymphocyte subsets in patients with active lupus nephritis [abstract no: MP230]","volume":"32","author":"Yap","year":"2017","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0234|cit234","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1136\/ard.2002.003574","article-title":"EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis","volume":"63","author":"Yee","year":"2004","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD002922.pub4-BIB0235|cit235","first-page":"356","article-title":"Cyclophosphamide (CTX) pulse therapy in lupus nephritis (LN): short term is better [abstract no: T235]","volume":"18","author":"Zhang","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0236|cit236","unstructured":"Zhang JH Yang H Cyclophosphamide (CYX) pulse therapy in lupus nephritis (ln): short term is better [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 290"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0237|cit237","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.reuma.2009.11.004","article-title":"Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study","volume":"6","author":"Andrade-Ortega","year":"2010","journal-title":"Reumatologia Clinica"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0238|cit238","first-page":"90A","article-title":"ACE inhibition reduces proteinuria, hematuria and renal expression of inflammatory mediators in human lupus nephritis [abstract]","volume":"12","author":"Antunes","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0239|cit239","unstructured":"Linnik MD Tansey MJ Joh T Dose dependent reduction in anti-dsDNA antibody levels observed with abetimus sodium through 52 weeks in the phase 3 ASPEN study (abetimus sodium in patients with a history of lupus nephritis) [abstract no: 1077] ACR\/ARHP Annual Scientific Meeting; 2008 Oct 24-29; San Francisco (CA) 2008"},{"issue":"Abstracts issue","key":"10.1002\/14651858.CD002922.pub4-BIB0240|cit240","first-page":"781A","article-title":"Interim analysis reveals dose dependent reduction in anti-dsDNA antibody levels with Abetimus sodium through 52 weeks in the phase 3 ASPEN study (Abetimus Sodium in Patients with a history of lupus Nephritis) [abstract no: SA-PO2958]","volume":"19","author":"Tansey","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD002922.pub4-BIB0241|cit241","first-page":"251","article-title":"Interim analysis reveals dose dependent reduction in anti-dsDNA antibody levels with Abetimus sodium through 52 weeks in the phase 3 ASPEN study (Abetimus Sodium in patients with a History of lupus Nephritis) [abstract no: THU0237]","volume":"68","author":"Tansey","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"Suppl 10","key":"10.1002\/14651858.CD002922.pub4-BIB0242|cit242","first-page":"749","article-title":"Efficacy, safety, and tolerability of BIIB023 as an adjunct to standard of care in subjects with lupus nephritis [abstract no: 749]","volume":"68","author":"Furie","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0243|cit243","first-page":"13A","article-title":"Results from the ATLAS Trial: a phase 2 study to evaluate efficacy and safety of BIIB023 in subjects with lupus nephritis [abstract no:TH-OR051]","volume":"27","author":"Rovin","year":"2016","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0244|cit244","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1681\/ASN.2008060665","article-title":"Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy","volume":"20","author":"Austin","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0245|cit245","first-page":"54A","article-title":"Long-term observations in a prospective clinical trial of prednisone, cyclosporine and cyclophosphamide for lupus membranous nephropathy (LMN) [abstract no: SU-FO048]","volume":"15","author":"Austin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0246|cit246","first-page":"81A","article-title":"Lupus membranous nephropathy: randomized controlled trial of prednisolone, cyclosporine and cyclophosphamide [abstract no: A0439]","volume":"11","author":"Austin","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0247|cit247","first-page":"1328","article-title":"Lupus membranous nephropathy: controlled trial of prednisolone, pulse cyclophosphamide, and cyclosporine A [abstract no: A0411]","volume":"7","author":"Austin","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0248|cit248","first-page":"119","article-title":"Clinical trial of cyclophosphamide plus azathioprine and pulse cyclophosphamide in lupus nephritis [abstract]","volume":"19","author":"Balow","year":"1981","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0249|cit249","first-page":"158","article-title":"Influence of treatment on the evolution of renal pathology in lupus nephritis [abstract]","volume":"25","author":"Balow","year":"1984","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0250|cit250","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1159\/000330685","article-title":"Antiproteinuric effect of chemokine C-C motif ligand 2 inhibition in subjects with acute proliferative lupus nephritis","volume":"34","author":"Ble","year":"2011","journal-title":"American Journal of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0251|cit251","first-page":"309A","article-title":"Histopathological outcome in proliferative lupus nephritis patients who did not achieve good response after randomized to eurolupus or high-dose IV cyclophosphamide [abstract no: TH-PO861]","volume":"20","author":"Chanchairujira","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0252|cit252","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/ki.1993.215","article-title":"Fish oil in lupus nephritis: clinical findings and methodological implications","volume":"44","author":"Clark","year":"1993","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0253|cit253","first-page":"309","article-title":"Fish oil in lupus nephritis a double-blind randomized crossover study [abstract no: 37P]","volume":"3","author":"Clark","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0254|cit254","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/07315724.2001.10719026","article-title":"Flaxseed in lupus nephritis: a two-year nonplacebo-controlled crossover study","volume":"20","author":"Clark","year":"2001","journal-title":"Journal of the American College of Nutrition"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0255|cit255","first-page":"143A","article-title":"Flaxseed in lupus nephritis: a two year randomized cross-over study [abstract no: T141]","volume":"9","author":"Clark","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0256|cit256","doi-asserted-by":"crossref","first-page":"e000120","DOI":"10.1136\/lupus-2015-000120","article-title":"A multicentre, randomised controlled study of enteric-coated mycophenolate sodium for the treatment of relapsed or resistant proliferative lupus nephritis: an Asian experience","volume":"3","author":"Anutrakulchai","year":"2016","journal-title":"Lupus Science & Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0257|cit257","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1191\/096120399678847380","article-title":"Recombinant human Dnase I (rhDNase) in patients with lupus nephritis","volume":"8","author":"Davis","year":"1999","journal-title":"Lupus"},{"issue":"1-4","key":"10.1002\/14651858.CD002922.pub4-BIB0258|cit258","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.prostaglandins.2005.08.001","article-title":"Captopril effect on prostaglandin E2, thromboxane B2 and proteinuria in lupus nephritis patients","volume":"78","author":"Daza","year":"2005","journal-title":"Prostaglandins & Other Lipid Mediators"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0259|cit259","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/annrheumdis-2017-211073","article-title":"A randomised double-blind, placebo-controlled trial of allogeneic umbilical cord-derived mesenchymal stem cell for lupus nephritis","volume":"76","author":"Deng","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"21","key":"10.1002\/14651858.CD002922.pub4-BIB0260|cit260","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.3760\/cma.j.issn.0366-6999.20140627","article-title":"Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis","volume":"127","author":"Feng","year":"2014","journal-title":"Chinese Medical Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0261|cit261","first-page":"S476","article-title":"Intravenous cyclophosphamide pulse therapy for severe lupus nephritis: finding an optimal dose and duration [abstract no: P1614]","volume":"3","author":"Frutos","year":"1997","journal-title":"Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0262|cit262","first-page":"201","article-title":"Clinical course of severe lupus nephritis during the controlled clinical trial of plasmapheresis [abstract]","volume":"31","author":"Hebert","year":"1987","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0263|cit263","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1053\/j.jrn.2011.03.002","article-title":"Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study","volume":"22","author":"Khajehdehi","year":"2012","journal-title":"Journal of Renal Nutrition"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0264|cit264","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1592\/phco.21.6.528.34549","article-title":"Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis","volume":"21","author":"Kuo","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0265|cit265","first-page":"556A","article-title":"Controlled trial of tacrolimus (FK506) vs intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis [abstract no: F-PO1006]","volume":"16","author":"Li","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0266|cit266","first-page":"956","article-title":"Treating lupus nephritis by a drug pair of radix astragali and rehmanniae radix combined with glucocorticoid: a preliminary clinical study","volume":"34","author":"Li","year":"2014","journal-title":"Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0267|cit267","first-page":"S272","article-title":"SLE trial shows fewer renal flares in LJP 394-treated patients with high affinity antibodies to LJP 394: 90-05 trial results [abstract]","volume":"43","author":"Alarcon-Segovia","year":"2000","journal-title":"Arthritis & Rheumatism"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0268|cit268","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/art.10763","article-title":"LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study","volume":"48","author":"Alarcon-Segovia","year":"2003","journal-title":"Arthritis & Rheumatism"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0269|cit269","first-page":"113A","article-title":"Integrated safety results from studies of LJP394 in SLE patients [abstract no: F-PO218]","volume":"15","author":"Hura","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0271|cit270","unstructured":"Linnik MD Hu JZ Heilbrunn KR Strand V Hurley FL Joh T Anti-dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus: results from 2 randomized controlled trials with LJP394 [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0270|cit271","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0272|cit272","first-page":"450A","article-title":"Reductions in anti-dsDNA antibodies and reduced risk of SLE renal flare and major SLE flare [abstract no: SA-PO695]","volume":"14","author":"Linnik","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0274|cit273","first-page":"449A","article-title":"Renal flare in SLE patients with impaired renal function in a RCT of LJP 394 [abstract no: SA-PO693]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0273|cit274","unstructured":"Tumlin JA Cardiel MH Furie RA Wallace DJ Hura C Foster T Reductions in 24 hour urine protein levels associated with treatment of lupus patients withLJP 394 in two randomized, placebo controlled, double-blind clinical trials [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0275|cit275","first-page":"121A","article-title":"Reductions in 24-hour urine protein levels associated with treatment of SLE patients with LJP394 in two randomized, placebo-controlled clinical trials [abstract no: F-PO256]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD002922.pub4-BIB0276|cit276","first-page":"253A","article-title":"The B-cell tolerogen LJP-394 reduces renal flares in patients with lupus nephritis: a prospective, double-blinded, placebo controlled trial [abstract]","volume":"12","author":"Tumlin","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0277|cit277","unstructured":"Cardiel MH LJP 394-90-09 Study Investigators Randomized, placebo controlled, double blind phase III trial for the evaluation of LJP 394 (Abetimus sodium) in the treatment of patients with SLE who are at risk of renal flare [abstract no: OP0053] Annual European Congress of Rheumatology EULAR; 2003 June 18-21; Lisbon (Portugal) 2003"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0278|cit278","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1002\/art.23673","article-title":"Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial","volume":"58","author":"Cardiel","year":"2008","journal-title":"Arthritis & Rheumatism"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0279|cit279","first-page":"113A","article-title":"Integrated safety results from studies of LJP394 in SLE patients [abstract no: F-PO218]","volume":"15","author":"Hura","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0281|cit280","unstructured":"Linnik MD Hu JZ Heilbrunn KR Strand V Hurley FL Joh T Anti-dsDNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus: results from 2 randomized controlled trials with LJP394 [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0280|cit281","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1002\/art.20980","article-title":"Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus","volume":"52","author":"Linnik","year":"2005","journal-title":"Arthritis & Rheumatism"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0282|cit282","first-page":"450A","article-title":"Reductions in anti-dsDNA antibodies and reduced risk of SLE renal flare and major SLE flare [abstract no: SA-PO695]","volume":"14","author":"Linnik","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0284|cit283","first-page":"449A","article-title":"Renal flare in SLE patients with impaired renal function in a RCT of LJP 394 [abstract no: SA-PO693]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0283|cit284","unstructured":"Tumlin JA Cardiel MH Furie RA Wallace DJ Hura C Foster T Reductions in 24 hour urine protein levels associated with treatment of lupus patients with LJP 394 in two randomized, placebo controlled, double-blind clinical trials [abstract] Lupus 2004; 7th International Congress on SLE and Related Conditions; 2004 May 9-13; New York (NY) 2004"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0285|cit285","first-page":"449A","article-title":"Efficacy results from a RCT of LJP 394 in SLE patients with history of renal disease [abstract no: SA-PO694]","volume":"14","author":"Tumlin","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0286|cit286","first-page":"791A","article-title":"The effect of LJP394 and concomitant immunosuppressive agents on levels of anti-dsDNA antibodies in SLE patients [abstract no: PUB137]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD002922.pub4-BIB0287|cit287","first-page":"121A","article-title":"Reductions in 24-hour urine protein levels associated with treatment of SLE patients with LJP394 in two randomized, placebo-controlled clinical trials [abstract no: F-PO256]","volume":"15","author":"Tumlin","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD002922.pub4-BIB0288|cit288","first-page":"449A","article-title":"Safety results from a RCT of LJP 394 in SLE patients with a history of renal disease [abstract no: SA-PO692]","volume":"14","author":"Wallace","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0289|cit289","first-page":"169","article-title":"Study on effect of Cordyceps sinensis and artemisinin in preventing recurrence of lupus nephritis","volume":"22","author":"Lu","year":"2002","journal-title":"Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0290|cit290","doi-asserted-by":"crossref","first-page":"606","DOI":"10.3109\/s10165-009-0218-5","article-title":"Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study","volume":"19","author":"Miyasaka","year":"2009","journal-title":"Modern Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0291|cit291","unstructured":"NCT00001212 Immunosuppressive drug therapy in membranous lupus nephropathy www.clinicaltrials.gov\/ct2\/show\/NCT00001212"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0292|cit292","unstructured":"Garg J A study to evaluate the safety of rituximab retreatment in subjects with lupus nephritis previously enrolled in study U2970g www.clinicalTrials.gov\/show\/NCT00404157"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0293|cit293","article-title":"Phase 3 study of tacrolimus (FK506) for lupus nephritis: a placebo controlled, double-blind multicenter, comparative study","author":"NCT00429377","journal-title":"www.clinicaltrials.gov\/ct2\/show\/NCT00429377"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0294|cit294","article-title":"A randomized, open-label study to compare the effect of cellcept plus corticosteroids, and cyclophosphamide plus corticosteroids followed by azathioprine, on remission rate in patients with lupus nephritis","author":"NCT00425438","journal-title":"www.clinicaltrials.gov\/ct2\/show\/NCT00425438"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0295|cit295","unstructured":"Jayne D Walsh M Corticosteroids in the maintenance therapy of proliferative lupus nephritis: a randomized pilot study (SIMPL) www.clinicaltrials.gov\/ct2\/show\/NCT00539799"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0296|cit296","article-title":"Effect of mesenchymal stem cell transplantation for lupus nephritis","author":"Tan","journal-title":"www.clinicaltrials.gov\/ct2\/show\/NCT00659217"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0297|cit297","unstructured":"Praga M Gema FJ Phase III, open, randomized, parallel-group clinical trial, to evaluate the efficacy and safety of treatment with prednisone, cyclosporine, mycophenolic acid versus prednisone and mycophenolic acid in lupus nephritis type III-IV-V www.clinicaltrials.gov\/ct2\/show\/NCT01299922"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0298|cit298","unstructured":"NCT01342016 A randomized, double-blind double dummy, parallel control and multi-center clinical trial to compare the efficacy and safety of tacrolimus capsules in treatment of lupus nephritis with leflunomide tablets www.clinicaltrials.gov\/ct2\/show\/NCT01342016"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0299|cit299","unstructured":"NCT01930890 BIIB023 long-term extension study in subjects with lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT01930890"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0300|cit300","unstructured":"NCT02176486 A phase 1b, randomized, double-blind, placebo-controlled, safety, tolerability and pharmacokinetic study of multiple rising doses of MLN9708 for the treatment of subjects with ISN\/RPS class III or IV lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02176486"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0301|cit301","first-page":"281","article-title":"Low does aspirin in patients with lupus nephritis [abstract]","volume":"33","author":"Pierucci","year":"1988","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0302|cit302","first-page":"283","article-title":"Acute effects of a thromboxane receptor antagonist on renal function in patients with lupus nephritis [abstract]","volume":"31","author":"Pierucci","year":"1987","journal-title":"Kidney International"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0303|cit303","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1056\/NEJM198902163200703","article-title":"Improvement of renal function with selective thromboxane antagonism in lupus nephritis","volume":"320","author":"Pierucci","year":"1989","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0304|cit304","first-page":"360A","article-title":"Short term cyclophosphamide (CP) bolus therapy for lupus nephritis [abstract]","volume":"5","author":"Schaumann","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0305|cit305","doi-asserted-by":"crossref","unstructured":"Schaumann D Hein R Schmidt RE Brunkhorst R Neumann KH Deicher H Intravenous cyclophosphamide (CP) pulse therapy for lupus nephritis - duration of induction therapy [abstract no: 028] International Symposium on Pathogenesis, Pathophysiology & Therapy of Glomerulonephritis; 1992 Dec 3-5; Bruges, Belgium 1992 60","DOI":"10.1159\/000186790"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0306|cit306","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3736\/jcim20070309","article-title":"Effect of intravenous drip infusion of cyclophosphamide with high-dose Astragalus injection in treating lupus nephritis","volume":"5","author":"Su","year":"2007","journal-title":"Zhong Xi Yi Jie He Xue Bao [Journal of Chinese Integrative Medicine]"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0307|cit307","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.1780140511","article-title":"Azathioprine in the treatment of systemic lupus erythematosus. A controlled study","volume":"14","author":"Sztejnbok","year":"1971","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0308|cit308","unstructured":"Wallace DJ Lisse J Stohl W McKay J Boling E Merrill JT Belimumab (BmAb) reduces SLE disease activity and demonstrates durable bioactivity at 76 weeks [abstract no: 2012] ACR\/ARHP Annual Scientific Meeting; 2006 Nov 11-15; Washington (DC) 2006"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0309|cit309","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/0961203307081340","article-title":"Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide","volume":"16","author":"Wang","year":"2007","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0310|cit310","first-page":"57","article-title":"Cyclophosphamide pulse therapy of systemic lupus erythematosus with renal involvement","volume":"19","author":"Hein","year":"1991","journal-title":"Immunitat und Infektion"},{"issue":"27-28","key":"10.1002\/14651858.CD002922.pub4-BIB0311|cit311","first-page":"1005","article-title":"Cyclophosphamide bolus therapy in lupus nephritis","volume":"118","author":"Witte","year":"1993","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD002922.pub4-BIB0312|cit312","first-page":"24","article-title":"Cyclophosphamide bolus therapy in lupus nephritis - status of the clinical study","volume":"21","author":"Witte","year":"1993","journal-title":"Immunitat und Infektion"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0313|cit313","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/j.1440-1797.2012.01574.x","article-title":"Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome","volume":"17","author":"Yap","year":"2012","journal-title":"Nephrology"},{"issue":"Suppl","key":"10.1002\/14651858.CD002922.pub4-BIB0314|cit314","first-page":"S99","article-title":"MMF vs CTX in the treatment of severe SLE patients [abstract no: P1610]","volume":"10","author":"Ye","year":"2001","journal-title":"Lupus"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0315|cit315","first-page":"1719","article-title":"Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis","volume":"23","author":"Yoshida","year":"1996","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0316|cit316","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/978-1-4899-1810-9_23","article-title":"Improvement of renal function with selective thromboxane A2 synthetase inhibitor, DP-1904 in lupus nephritis","volume":"433","author":"Yoshida","year":"1997","journal-title":"Advances in Experimental Medicine & Biology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0317|cit317","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s12013-014-0437-z","article-title":"Effect of Rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis","volume":"72","author":"Zhang","year":"2015","journal-title":"Cell Biochemistry & Biophysics"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0318|cit318","first-page":"983","article-title":"Intervention of liuwei dihuang pill on lupus nephropathy treated with cyclophosphamide and glucocorticoids","volume":"25","author":"Zheng","year":"2005","journal-title":"Zhongguo Zhongxiyi Jiehe Zazhi [Chinese Journal of Integrated Traditional and Western Medicine]"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0319|cit319","unstructured":"Bijl M Comparison of short course cyclophosphamide followed by mycophenolate mofetil versus long course cyclophosphamide in the treatment of proliferative lupus nephritis www.controlled-trials.com\/ISRCTN34634478"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0320|cit320","unstructured":"Li Z The intensive therapy of severe lupus nephritis: a multicenter, randomized, controlled prospective clinical trial www.chictr.org.cn\/showprojen.aspx?proj=8948"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0321|cit321","unstructured":"Mei C Treatment of severe lupus nephritis with tacrolimus (FK 506) based immunosuppression www.chictr.org.cn\/showprojen.aspx?proj=8607"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0322|cit322","unstructured":"Gupta KL Comparison of two steroid dose regimen in lupus nephritis www.ctri.nic.in\/Clinicaltrials\/pdf_generate.php?trialid=13735&EncHid=&modid=&compid=%27,%2713735det%27"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0323|cit323","article-title":"A study to compare the efficacy of cyclophosphamide versus multi-drug therapy in the treatment of lupus nephritis","author":"Gupta","journal-title":"www.ctri.nic.in\/Clinicaltrials\/showallp.php?mid1=19083&EncHid=&userName=CTRI\/2017\/05\/008697"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0324|cit324","unstructured":"Chartapisak W Enteric coat mycophenolate sodium versus intravenous cyclophosphamide for severe paediatric lupus nephritis www.isrctn.com\/ISRCTN66475575"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0325|cit325","unstructured":"Li LS To compare the efficacy and safety of FK506 vs IVC in the treatment of class III-IV LN www.clinicaltrials.gov\/ct2\/show\/NCT00302549"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0326|cit326","unstructured":"NCT00705367 Phase I study in China - tolerability of a single dose of abatacept 30 mg\/kg www.clinicaltrials.gov\/show\/NCT00705367"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0327|cit327","unstructured":"Hu W To compare the efficacy and safety of tripterygium (TW) vs AZA in the maintenance therapy for lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT00881309"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0328|cit328","unstructured":"Liu ZH Long-term study of multi-target therapy as maintenance treatment for lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT01056237"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0329|cit329","unstructured":"NCT01172002 A randomized multicenter trial comparing leflunomide and azathioprine as remission-maintaining treatment for proliferative lupus glomerulonephritis www.clinicaltrials.gov\/ct2\/show\/NCT01172002"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0330|cit330","unstructured":"Belaigues B Weaning of Immunosuppression in Nephritis of Lupus (WIN-Lupus) www.clinicaltrials.gov\/ct2\/show\/NCT01284725"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0331|cit331","unstructured":"NCT01639339 A phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of belimumab plus standard of care versus placebo plus standard of care in adult subjects with active lupus nephritis (BLISS-LN) www.clinicaltrials.gov\/ct2\/show\/NCT01639339"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0332|cit332","unstructured":"NCT01714817 Efficacy and safety study of abatacept to treat lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT01714817"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0333|cit333","unstructured":"Wegener W Phase Ib study of SC milatuzumab in SLE www.clinicaltrials.gov\/ct2\/show\/NCT01845740"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0334|cit334","unstructured":"Piyaphanee N Pattaragarn A Efficacy and infectious complications of induction therapy with low-dose versus high-dose intravenous cyclophosphamide for proliferative lupus nephritis in children www.clinicaltrials.gov\/ct2\/show\/NCT01861561"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0335|cit335","unstructured":"NCT02226341 Open-label prospective randomized study to determine the efficacy and safety of two dosing regimens of ACTHar in the treatment of proliferative lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02226341"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0336|cit336","unstructured":"NCT02256150 A multi-center, randomized, controlled, open-label clinical study to evaluate the efficacy and safety of mizoribine in comparison with cyclophosphamide in the treatment of lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02256150"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0337|cit337","unstructured":"Diamond B Wofsy D Dall'Era M Aranow C Rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis (ITN055AI) (CALIBRATE) www.clinicaltrials.gov\/ct2\/show\/NCT02260934"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0338|cit338","unstructured":"NCT02457221 A phase III, randomized, open, parallel-controlled, multi-center study to compare the efficacy and safety of tacrolimus capsules and cyclophosphamide injection in treatment of lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02457221"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0339|cit339","unstructured":"NCT02547922 A multicentre, randomised, double-blind, placebo-controlled, phase 2 study evaluating the efficacy and safety of anifrolumab in adult subjects with active proliferative lupus nephritis (TULIP-LN1) www.clinicaltrials.gov\/ct2\/show\/NCT02547922"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0340|cit340","unstructured":"NCT02550652 A randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety and efficacy of obinutuzumab in subjects with ISN\/RPS 2003 class III or IV lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02550652"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0341|cit341","unstructured":"Chan DT A randomized open-label study to evaluate the efficacy and safety of tacrolimus and corticosteroids in comparison with mycophenolate mofetil and corticosteroids in subjects with class III\/IV\u00b1V lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02630628"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0342|cit342","unstructured":"NCT02770170 A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year treatment in patients with lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02770170"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0343|cit343","unstructured":"Bao C Iguratimod as treatment for active lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02936375"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0344|cit344","unstructured":"Yap D A randomized, controlled double-blind study comparing the efficacy and safety of orelvo (voclosporin) (23.7 mg twice daily) with placebo in achieving renal response in subjects with active lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT02954939"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0345|cit345","unstructured":"Dooley MA Aurinia renal response in active lupus with voclosporin www.clinicaltrials.gov\/ct2\/show\/NCT03021499"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0346|cit346","unstructured":"Yu XQ Efficacy and safety of artesunate plus standard of care in active lupus nephritis www.clinicaltrials.gov\/ct2\/show\/NCT03214731"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0347|cit347","unstructured":"PER-062-15 A multicentre, randomised, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of two doses of anifrolumab in adult subjects with active proliferative lupus nephritis www.ins.gob.pe\/ensayosclinicos\/rpec\/recuperarECPBNuevoEN.asp?numec=062-15"},{"issue":"3 Suppl 90","key":"10.1002\/14651858.CD002922.pub4-BIB0348|cit348","first-page":"S30","article-title":"RING, an investigator-initiated trial aimed at testing the efficacy of rituximab in refractory lupus nephritis: rationale, trial design and call for participation [abstract]","volume":"33","author":"Houssiau","year":"2015","journal-title":"Clinical & Experimental Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0349|cit349","unstructured":"Lightstone L Phase 3 open label randomised multicentre controlled trial of rituximab and mycophenolate mofetil without oral steroids for the treatment of lupus nephritis (RITUXILUP) www.clinicaltrials.gov\/ct2\/show\/NCT01773616"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0350|cit350","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/kel039","article-title":"An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period","volume":"45","author":"Adler","year":"2006","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0351|cit351","unstructured":"Australia New Zealand Dialysis Transplant Registry ANZDATA Registry. 39th Report, Chapter 1: Incidence of End Stage Kidney Disease www.anzdata.org.au\/anzdata\/AnzdataReport\/39thReport\/c01_incidence_v5.0_20170418.pdf"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0352|cit352","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0272-6386(97)90029-9","article-title":"Treatment of lupus nephritis: a meta-analysis of clinical trials","volume":"29","author":"Bansal","year":"1997","journal-title":"American Journal of Kidney Diseases"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0353|cit353","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.1996.03540080059030","article-title":"Improving the quality of reporting of randomized controlled trials. The CONSORT statement","volume":"276","author":"Begg","year":"1996","journal-title":"JAMA"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0354|cit354","doi-asserted-by":"crossref","first-page":"e0144548","DOI":"10.1371\/journal.pone.0144548","article-title":"The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis","volume":"10","author":"Cao","year":"2015","journal-title":"PLoS ONE [Electronic Resource]"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0355|cit355","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1177\/0961203309106831","article-title":"The Euro-lupus project: epidemiology of systemic lupus erythematosus in Europe","volume":"18","author":"Cervera","year":"2009","journal-title":"Lupus"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0356|cit356","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00296-017-3733-2","article-title":"Treatment for lupus nephritis: an overview of systematic reviews and meta-analyses","volume":"37","author":"Chen","year":"2017","journal-title":"Rheumatology International"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0357|cit357","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1038\/sj.ki.5000243","article-title":"Outcomes in African Americans and Hispanics with lupus nephritis","volume":"69","author":"Contreras","year":"2006","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0358|cit358","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/art.30293","article-title":"Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006","volume":"63","author":"Costenbader","year":"2011","journal-title":"Arthritis & Rheumatism"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0359|cit359","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1080\/13548506.2011.554566","article-title":"Health-related quality of life in patients with systemic lupus erythematosus and proliferative lupus nephritis","volume":"16","author":"Daleboudt","year":"2011","journal-title":"Psychology Health & Medicine"},{"issue":"7305","key":"10.1002\/14651858.CD002922.pub4-BIB0360|cit360","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bmj.323.7305.157","article-title":"Systematic reviews in health care: Systematic review of evaluations of diagnostic and screening tests","volume":"323","author":"Deeks","year":"2001","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0361|cit361","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1620\/tjem.227.281","article-title":"A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis","volume":"227","author":"Deng","year":"2012","journal-title":"Tohoku Journal of Experimental Medicine"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0362|cit362","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/ki.1997.162","article-title":"Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network","volume":"51","author":"Dooley","year":"1997","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0363|cit363","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/nep.12006","article-title":"Mycophenolate mofetil versus azathioprine as maintenance therapy for lupus nephritis: a meta-analysis","volume":"18","author":"Feng","year":"2013","journal-title":"Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0364|cit364","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/rheumatology\/kev003","article-title":"Assessment of long-term remission in lupus nephritis patients: a retrospective analysis over 30 years","volume":"54","author":"Fernandes das Neves","year":"2015","journal-title":"Rheumatology"},{"issue":"7650","key":"10.1002\/14651858.CD002922.pub4-BIB0365|cit365","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0366|cit366","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0367|cit367","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0368|cit368","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.autrev.2015.09.006","article-title":"Tacrolimus use in lupus nephritis: a systematic review and meta-analysis","volume":"15","author":"Hannah","year":"2016","journal-title":"Autoimmunity Reviews"},{"issue":"7414","key":"10.1002\/14651858.CD002922.pub4-BIB0369|cit369","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0370|cit370","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. 2011 Available from www.cochrane-handbook.org"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0371|cit371","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0372|cit372","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1523-1755.2000.00832.x","article-title":"Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide","volume":"57","author":"Ioannidis","year":"2000","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0373|cit373","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0374|cit374","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/MD.0b013e3181e93d00","article-title":"Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis","volume":"89","author":"Kamanamool","year":"2010","journal-title":"Medicine"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0375|cit375","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1681\/ASN.2006090992","article-title":"Severe lupus nephritis: racial differences in presentation and outcome","volume":"18","author":"Korbet","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0376|cit376","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/0961203309357763","article-title":"Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis","volume":"19","author":"Lee","year":"2010","journal-title":"Lupus"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0377|cit377","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0961203310389486","article-title":"Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials","volume":"20","author":"Lee","year":"2011","journal-title":"Lupus"},{"issue":"14","key":"10.1002\/14651858.CD002922.pub4-BIB0378|cit378","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/0961203315595131","article-title":"Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials","volume":"24","author":"Lee","year":"2015","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0379|cit379","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/art.21625","article-title":"The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials","volume":"54","author":"Criteria","year":"2006","journal-title":"Arthritis & Rheumatism"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0380|cit380","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2165\/11635030-000000000-00000","article-title":"Efficacy and safety of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: a meta-analysis of randomized controlled trials","volume":"72","author":"Liu","year":"2012","journal-title":"Drugs"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0381|cit381","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/rheumatology\/kep120","article-title":"Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression","volume":"48","author":"Mak","year":"2009","journal-title":"Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0382|cit382","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1093\/rheumatology\/ket429","article-title":"Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis","volume":"53","author":"Maneiro","year":"2014","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0383|cit383","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/0961203306071710","article-title":"A review of health related quality of life in systemic lupus erythematosus","volume":"15","author":"McElhone","year":"2006","journal-title":"Lupus"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0384|cit384","doi-asserted-by":"crossref","first-page":"f2914","DOI":"10.1136\/bmj.f2914","article-title":"Demystifying trial networks and network meta-analysis","volume":"346","author":"Mills","year":"2013","journal-title":"BMJ"},{"issue":"9193","key":"10.1002\/14651858.CD002922.pub4-BIB0385|cit385","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","article-title":"Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses","volume":"354","author":"Moher","year":"1999","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0386|cit386","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1002\/art.10138","article-title":"Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine","volume":"46","author":"Mok","year":"2002","journal-title":"Arthritis & Rheumatism"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0387|cit387","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1186\/ar2093","article-title":"Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis","volume":"8","author":"Moore","year":"2006","journal-title":"Arthritis Research & Therapy"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0388|cit388","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1093\/ndt\/gfm245","article-title":"The long-term outcome of 93 patients with proliferative lupus nephritis","volume":"22","author":"Moroni","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"9894","key":"10.1002\/14651858.CD002922.pub4-BIB0389|cit389","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0140-6736(13)60889-2","article-title":"Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment","volume":"382","author":"Murphy","year":"2013","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0390|cit390","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.ajkd.2016.12.008","article-title":"Induction and maintenance immunosuppression treatment of proliferative lupus nephritis: a network meta-analysis of randomized trials","volume":"70","author":"Palmer","year":"2017","journal-title":"American Journal of Kidney Disease"},{"issue":"9","key":"10.1002\/14651858.CD002922.pub4-BIB0391|cit391","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1191\/096120398678920776","article-title":"Flares in lupus nephritis: incidence, impact on renal survival and management","volume":"7","author":"Ponticelli","year":"1998","journal-title":"Lupus"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0392|cit392","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.2009.412","article-title":"Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis","volume":"77","author":"Radhakrishnan","year":"2010","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0393|cit393","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1053\/j.ajkd.2013.11.023","article-title":"Lupus nephritis: the evolving role of novel therapeutics","volume":"63","author":"Rovin","year":"2014","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0394|cit394","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0395|cit395","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0396|cit396","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2215\/CJN.02350314","article-title":"ESRD from lupus nephritis in the United States","volume":"10","author":"Sexton","year":"2014","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0397|cit397","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3899\/jrheum.160041","article-title":"Treatments for lupus nephritis: a systematic review and network metaanalysis","volume":"44","author":"Singh","year":"2016","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0398|cit398","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s10067-011-1778-2","article-title":"Predictive value of remission status after 6 months induction therapy in patients with proliferative lupus nephritis: a retrospective analysis","volume":"30","author":"So","year":"2011","journal-title":"Clinical Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0399|cit399","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1191\/096120300678828424","article-title":"Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology","volume":"9","author":"Stand","year":"2000","journal-title":"Lupus"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0400|cit400","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/acr.22032","article-title":"Experiences and perspectives of adults living with systemic lupus erythematosus: thematic synthesis of qualitative studies","volume":"65","author":"Sutanto","year":"2013","journal-title":"Arthritis Care & Research"},{"issue":"6","key":"10.1002\/14651858.CD002922.pub4-BIB0401|cit401","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1002\/art.39594","article-title":"Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis","volume":"68","author":"Tektonidou","year":"2016","journal-title":"Arthritis & Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD002922.pub4-BIB0402|cit402","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/rheumatology\/39.11.1249","article-title":"The prevalence and associations of fatigue in systemic lupus erythematosus","volume":"39","author":"Tench","year":"2000","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0403|cit403","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.3899\/jrheum.140050","article-title":"Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis","volume":"41","author":"Tian","year":"2014","journal-title":"Journal of Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD002922.pub4-BIB0404|cit404","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3899\/jrheum.141650","article-title":"Immunosuppressive therapies for the maintenance treatment of proliferative lupus nephritis: a systematic review and network metaanalysis","volume":"42","author":"Tian","year":"2015","journal-title":"Journal of Rheumatology"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0405|cit405","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3899\/jrheum.100130","article-title":"Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis","volume":"38","author":"Touma","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD002922.pub4-BIB0406|cit406","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/acr.22591","article-title":"Diagnosis, monitoring, and treatment of systemic lupus erythematosus: a systematic review of clinical practice guidelines","volume":"67","author":"Tunnicliffe","year":"2015","journal-title":"Arthritis Care & Research"},{"issue":"3","key":"10.1002\/14651858.CD002922.pub4-BIB0407|cit407","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/annrheumdis-2016-209519","article-title":"A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)","volume":"76","author":"Vollenhoven","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0408|cit408","first-page":"2595","article-title":"A comparison of the quality of life of patients with systemic lupus erythematosus with and without endstage renal disease","volume":"26","author":"Vu","year":"1999","journal-title":"Journal of Rheumatology"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0409|cit409","doi-asserted-by":"crossref","first-page":"968","DOI":"10.2215\/CJN.01200307","article-title":"Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis","volume":"2","author":"Walsh","year":"2007","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0410|cit410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/ndt\/gfs285","article-title":"Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis","volume":"28","author":"Weidenbusch","year":"2013","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD002922.pub4-BIB0411|cit411","first-page":"7407919","article-title":"Immunosuppressive treatment for lupus nephritis: long-term results in 178 patients","author":"Zakharova","year":"2016","journal-title":"BioMed Research International"},{"issue":"5","key":"10.1002\/14651858.CD002922.pub4-BIB0412|cit412","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s11255-015-1201-z","article-title":"The effect of calcineurin inhibitors in the induction and maintenance treatment of lupus nephritis: a systematic review and meta-analysis","volume":"48","author":"Zhang","year":"2016","journal-title":"International Urology & Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0413|cit413","first-page":"287","article-title":"Meta-analysis of calcineurin inhibitor in the treatment of lupus nephritis","volume":"49","author":"Zhou","year":"2011","journal-title":"Zhonghua Erke Zazh [Chinese Journal of Pediatrics]"},{"issue":"7","key":"10.1002\/14651858.CD002922.pub4-BIB0414|cit414","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/ndt\/gfm066","article-title":"Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhu","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD002922.pub4-BIB0415|cit415","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0416|cit416","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922.pub2","article-title":"Treatment for lupus nephritis","author":"Flanc","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD002922.pub4-BIB0417|cit417","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1053\/j.ajkd.2003.10.012","article-title":"Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"43","author":"Flanc","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"12","key":"10.1002\/14651858.CD002922.pub4-BIB0418|cit418","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002922.pub3","article-title":"Treatment for lupus nephritis","author":"Henderson","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD002922.pub4-BIB0419|cit419","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.ajkd.2012.08.041","article-title":"Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials","volume":"61","author":"Henderson","year":"2013","journal-title":"American journal of kidney diseases"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD002922.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T21:05:40Z","timestamp":1720386340000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD002922.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,29]]},"references-count":420,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002922.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,29]]}}}